Pallas Capital Advisors LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,072 shares of the insurance provider's stock, valued at approximately $2,136,000.
Other large investors have also modified their holdings of the company. Revolve Wealth Partners LLC purchased a new stake in shares of Humana in the 4th quarter valued at $202,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Humana by 1.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 330,906 shares of the insurance provider's stock worth $83,954,000 after buying an additional 5,497 shares in the last quarter. Apollon Wealth Management LLC increased its stake in shares of Humana by 6.0% during the fourth quarter. Apollon Wealth Management LLC now owns 2,983 shares of the insurance provider's stock worth $757,000 after buying an additional 168 shares during the period. Savant Capital LLC raised its holdings in Humana by 1.9% in the fourth quarter. Savant Capital LLC now owns 3,327 shares of the insurance provider's stock valued at $844,000 after acquiring an additional 63 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in Humana by 151.4% in the fourth quarter. Van ECK Associates Corp now owns 3,366 shares of the insurance provider's stock worth $854,000 after acquiring an additional 2,027 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on HUM shares. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Guggenheim initiated coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective for the company. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Finally, Barclays decreased their target price on Humana from $322.00 to $273.00 and set an "equal weight" rating for the company in a research note on Monday, June 2nd. Sixteen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana currently has an average rating of "Hold" and a consensus target price of $284.48.
Check Out Our Latest Research Report on Humana
Humana Price Performance
HUM traded down $1.12 during midday trading on Tuesday, reaching $231.95. 1,137,367 shares of the company's stock were exchanged, compared to its average volume of 1,784,912. The business's 50-day moving average price is $252.85 and its 200 day moving average price is $264.23. The stock has a market capitalization of $27.99 billion, a PE ratio of 23.31, a P/E/G ratio of 2.05 and a beta of 0.43. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.23 EPS. As a group, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.
Humana Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.53%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is 25.04%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
